Nifty 50
- SBI₹1,13526.40 (2.38%)
- Titan Company₹4,648.10-259.90 (-5.30%)
- Cipla₹1,417.5029.50 (2.13%)
- HDFC Life Insurance ₹575.50-19.55 (-3.29%)
- Tata Consumer ₹1,130.9018.50 (1.66%)
- Hindalco Industries₹900-27.75 (-2.99%)
- Apollo Hospitals₹8,821108.50 (1.25%)
- BSE₹3,755.70-109.20 (-2.83%)
- ITC₹296.603.30 (1.13%)
- Tata Motors PV₹252.55-6.65 (-2.57%)
- UltraTech Cement₹12,428138.00 (1.12%)
- Bajaj Finance₹1,093.85-27.25 (-2.43%)
- Dr. Reddy's Labs₹1,398.2010.20 (0.73%)
- Eternal₹366-9.05 (-2.41%)
- ONGC₹2251.48 (0.66%)
- Adani Enterprises₹2,688-57.10 (-2.08%)
- Trent₹3,19013.70 (0.43%)
- InterGlobe Aviation₹5,499.30-111.70 (-1.99%)
- Power Grid Corp₹259.101.10 (0.43%)
- Jio Financial ₹224.50-4.46 (-1.95%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Open Free Demat Account
Gujarat Themis Share Price Today
As of 19-11-2026 01:42, Gujarat Themis Biosyn Ltd. share price today is ₹0, with a change of ₹-349.00 (-100.00%) from the previous close of ₹349. The stock opened at ₹347 and traded between ₹346.05 and ₹364.3, with a total traded volume of 138794 shares. The company has a market capitalization of ₹4542.3 Cr in the Pharmaceuticals & Biotechnology sector. while its 52-week high and low are ₹470.05 and ₹225.05, respectively.
Gujarat Themis Biosyn Ltd. valuation metrics include a P/E ratio of 105.9, and book value of ₹15.10. Profitability indicators show ROE of 16.22% along with a dividend yield of 0.2%. Gujarat Themis Biosyn Ltd. has reported revenue of ₹178.85 Cr and net profit of ₹42.89 Cr.
Gujarat Themis Biosyn Ltd. technical indicators include Day RSI at 39.86, Day MFI at 63.07, Day ADX at 19.37. Additional indicators include Commodity Channel Index (CCI) at -64 and Williams %R at -92.3. Momentum indicators show Day MACD at -1.89, Day MACD Signal Line at -1.3, DayATR at 19.11. Rate of Change indicators for Gujarat Themis Biosyn Ltd. include ROC125 at -2.04 and ROC21 at -6.53.
Exponential moving averages include EMA5 at ₹367.9, EMA10 at ₹372.6, EMA12 at ₹373, EMA20 at ₹373.8, EMA26 at ₹374.9, EMA50 at ₹378.7, EMA100 at ₹378.4, EMA200 at ₹370.8. Simple moving averages include SMA5 at ₹375.2, SMA10 at ₹379.6, SMA20 at ₹367.8, SMA30 at ₹369.8, SMA50 at ₹387.4, SMA100 at ₹382, SMA150 at ₹378.7, SMA200 at ₹358.7.
Support levels for Gujarat Themis are placed at First Support ₹341.00, Second Support ₹333.00, Third Support ₹321.00. Resistance levels are seen at First Resistance ₹361.00, Second Resistance ₹373.00, Third Resistance ₹381.00. Gujarat Themis Biosyn Ltd. shareholding pattern shows promoter holding at 59.33%, FII holding at 3.8%, DII holding at 0%, public holding at 24.21%.
Gujarat Themis Performance
Price Movement
₹346.05
₹364.30
1 Year Performance
₹225.05
₹470.05
Markets Today
Historical Performance
Gujarat Themis Fundamentals
Gujarat Themis Financials
Indicator | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Total Revenue | 47.46 | 43.79 | 44.23 | 43.37 | 42.35 |
| Operating Expense | 29.73 | 23 | 24.87 | 22.06 | 21.41 |
| Operating Profit | 17.73 | 20.79 | 19.36 | 21.31 | 20.94 |
| Depreciation | 3.99 | 3.97 | 4.04 | 3.89 | 2.96 |
| Interest | 6.36 | 1.79 | 1.91 | 0.96 | 0.04 |
| Tax | 2.59 | 4.10 | 3.45 | 4.41 | 4.50 |
| Net Profit | 8.47 | 11.07 | 10.89 | 12.46 | 14.26 |
Gujarat Themis Technicals
Gujarat Themis Biosyn Ltd. EMA & SMA
₹364.20
↗ Bullish Moving Average
0
↘ Bearish Moving Average
16
Gujarat Themis Support and Resistance
Resistance
Support
Technical Indicators
About Gujarat Themis Biosyn Limited Stock Share Price
Gujarat Themis Biosyn Limited (GTBL) is a small‑cap pharmaceutical company primarily engaged in the manufacturing of fermentation‑based active pharmaceutical ingredients (APIs) and biotechnology products. Headquartered in Valsad, Gujarat, India, the company was incorporated in 1981 and is promoted by Jayshree D. Patel. The Gujarat Themis Biosyn share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.
Market sentiment around the Gujarat Themis Biosyn stock price often mirrors shifts in demand for fermentation‑based APIs, global pharmaceutical supply chain trends, and investor views on the healthcare sector’s growth prospects. Factors such as capacity expansion, regulatory compliance, competitive intensity from other API manufacturers, and government policies on pharmaceutical production influence near‑term market valuation and medium‑term earnings forecasts. All these factors must be closely monitored to have an idea about the Gujarat Themis Biosyn share price movements.
The Gujarat Themis Biosyn live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Gujarat Themis Biosyn live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market.
Furthermore, monitoring the Gujarat Themis Biosyn share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. The Gujarat Themis Biosyn stock price remains sensitive to pharmaceutical sector trends.
Gujarat Themis Biosyn Limited Company Fundamentals
A. Company Background
Gujarat Themis Biosyn Limited was incorporated in 1981. The company’s registered office is located in Valsad, Gujarat, India. GTBL was originally incorporated as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd, and the company’s name was changed from Gujarat Themis Biosyn Limited to its current name on October 21, 1999. GTBL is a small‑cap pharmaceutical company primarily engaged in the manufacturing of fermentation‑based active pharmaceutical ingredients (APIs) and biotechnology products. The company operates in the Pharmaceuticals and Biotechnology sector, focusing on the production of APIs such as D‑Cycloserine, an antibiotic used in the treatment of tuberculosis and other bacterial infections. As a small‑cap entity, it operates in a competitive environment within the API manufacturing industry. The company is listed on the Bombay Stock Exchange (BSE) under the scrip code 506879 and on the National Stock Exchange (NSE) under the symbol GUJTHEM.
B. Product Lines
- Fermentation‑based Active Pharmaceutical Ingredients (APIs), including D‑Cycloserine
- Biotechnology products for pharmaceutical applications
- Pharmaceutical formulations
- Bulk drugs and drug intermediates
- Speciality chemical products for the healthcare sector
C. Company Revenue Model
- Primary revenue from manufacture and sale of fermentation‑based APIs and biotechnology products to pharmaceutical companies.
- Volume‑driven revenue based on the quantity of APIs produced and sold to domestic and international markets.
- Pricing determined by raw material costs, regulatory approvals, and competitive intensity, affecting overall revenue generation.
- Revenue from export markets, with the company having a presence in regulated and semi‑regulated markets.
- Focus on expanding product portfolio in niche API segments and increasing manufacturing capacity.
- Investment in research and development to develop new fermentation‑based products.
- Seasonal variations in demand for certain therapeutic products affecting revenue patterns.
- Government policy changes on drug pricing and pharmaceutical manufacturing incentives influencing revenue stability.
D. Geographic Presence
- Headquartered in Valsad, Gujarat, India.
- Operations focused on domestic API manufacturing with exports to select international markets.
- Manufacturing facilities located in Gujarat.
- Serves pharmaceutical customers across multiple states within India and internationally.
E. Key Milestones
- 1981 – Company incorporated as a joint sector company with GIIC and Chemosyn (P) Ltd.
- 1999 – Name changed to Gujarat Themis Biosyn Limited on October 21.
- 2021 – Became a division of Themis Medicare Limited.
- 2025 – Product portfolio expansion in fermentation‑based APIs.
F. Industry Perspective
Gujarat Themis Biosyn operates in the pharmaceutical industry, specifically the fermentation‑based API segment. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2025 and is projected to reach USD 2.3 trillion by 2030, growing at a CAGR of 7.1%. India is the 3rd largest pharmaceutical market by volume and 14th by value. The Indian pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15‑17%. India supplies over 50% of global demand for various vaccines and 40% of generic demand in key markets. The fermentation‑based API segment is a specialised niche within the broader API market, driven by increasing demand for antibiotics and other fermentation‑derived therapeutics. The government’s Production Linked Incentive (PLI) scheme for pharmaceuticals and the focus on reducing import dependence for APIs are key growth drivers. Challenges include volatile raw material prices, stringent regulatory compliance (including USFDA and WHO GMP standards), intense competition from Chinese API manufacturers, and the need for continuous research and development investment.
Gujarat Themis Biosyn Limited Stock Market Presence: Listings & Index Representation
Gujarat Themis Biosyn is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol GUJTHEM and on the Bombay Stock Exchange (BSE) with the scrip code 506879. The ISIN for the company is INE942C01045. Its listing on both exchanges ensures that the Gujarat Themis Biosyn share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed in December 2003 through a public offer of 40,000,000 equity shares at a price of Rs 48 per share. The company forms part of several benchmark indices that represent broad market segments. Gujarat Themis Biosyn is included in indices such as the S&P BSE Healthcare, S&P BSE MidSmallCap, S&P BSE SmallCap, and S&P BSE AllCap. Being represented in multiple indices enhances the visibility and liquidity of the Gujarat Themis Biosyn stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups within India’s pharmaceutical landscape.
Gujarat Themis Biosyn Limited Stock Performance and Share Price History
The performance and share price history of Gujarat Themis Biosyn Limited are influenced by a complex mix of operational, regulatory, and macroeconomic factors. A primary driver is the fluctuation in demand for fermentation‑based APIs, as any slowdown in the pharmaceutical supply chain directly impacts revenue visibility, often leading to corrections in the Gujarat Themis Biosyn share price. Government policies regarding drug pricing, particularly the National Pharmaceutical Pricing Authority (NPPA) price caps on essential medicines, also play a critical role. For instance, when the government imposes price controls on certain APIs or formulations, concerns about profitability emerge, putting pressure on the Gujarat Themis Biosyn stock price. Conversely, favourable policy moves, such as the PLI scheme for pharmaceuticals, have historically boosted investor sentiment.
Another major factor is competition from both large multinational pharmaceutical companies and smaller generic API manufacturers, which can alter long‑term growth projections and influence the Gujarat Themis Biosyn share price. The company’s product pipeline progress, driven by research and development investments and new drug master file filings, directly impacts revenue visibility. Quarterly financial results, especially net profit and sales volume figures, cause immediate swings in the Gujarat Themis Biosyn stock price. Additionally, broader market trends, developments in global healthcare spending, and currency fluctuations affecting export realizations contribute to volatility. Historically, the Gujarat Themis Biosyn share price has shown resilience during the COVID-19 pandemic but has also faced sharp declines during periods of regulatory uncertainty. Overall, the Gujarat Themis Biosyn stock price remains a barometer of both India’s pharmaceutical export capabilities and the regulatory stability affecting drugmakers.
The 52‑week high and low of the stock are largely dictated by sentiment shifts and external shocks. When the company receives new product approvals and launches products in regulated markets, the Gujarat Themis Biosyn share price tends to rally toward its 52‑week high; conversely, any regulatory warning letter or delay in approval can drive the Gujarat Themis Biosyn share price down to a new low. The Gujarat Themis Biosyn share price also hits its peak when management announces capacity expansion, while a sharp spike in input costs or pricing pressure pushes the Gujarat Themis Biosyn share price toward the yearly bottom. Broader market sell‑offs, such as during economic slowdowns, often drag the Gujarat Themis Biosyn share price to multi‑month lows, even if fundamentals are sound. Conversely, a strong USFDA approval spree can lift the Gujarat Themis Biosyn share price to a new 52‑week high. Additionally, quarterly earnings misses or regulatory compliance concerns have historically pressured the Gujarat Themis Biosyn share price to test its lowest levels in a given year.
The Gujarat Themis Biosyn share price has exhibited exceptional long‑term growth over the past decade, shaped by the company’s focus on fermentation‑based APIs and broader pharmaceutical industry cycles. The Gujarat Themis Biosyn share price recorded a 10‑year total return of 6,518.99%, demonstrating spectacular long‑term wealth creation. The Gujarat Themis Biosyn share price delivered a 5‑year return of 1,073.23% and a 3‑year return of 295.04%. The Gujarat Themis Biosyn share price reached a 52‑week high of ₹479.00 and a 52‑week low of ₹225.05, indicating a wide trading range. The Gujarat Themis Biosyn share price has shown a 1‑month return of approximately 8.10% and a 6‑month return of 42.15%. The Gujarat Themis Biosyn share price has given a return of 21.08% in the last 1 year as of May 2026, indicating consistent positive momentum. The Gujarat Themis Biosyn share price has a market capitalisation of approximately ₹4,342 crore.
The Gujarat Themis Biosyn stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a revenue of ₹150.8 crore and profit after tax of ₹48.77 crore in FY 2025, the Gujarat Themis Biosyn stock price showed a positive reaction. The Gujarat Themis Biosyn stock price has shown a pattern of strong positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Gujarat Themis Biosyn stock price. Corporate developments, including strategic announcements such as the expansion of manufacturing capacity and the development of new fermentation‑based APIs, have also influenced short‑term fluctuations in the Gujarat Themis Biosyn share price. The Gujarat Themis Biosyn share price reached its 52‑week high before declining to its 52‑week low, reflecting normal volatility inherent in the pharmaceutical space. The Gujarat Themis Biosyn share price has shown a year‑to‑date return of 46.34% as of 2025, indicating strong momentum in the current fiscal year. Comprehending these patterns in the Gujarat Themis Biosyn share price is instrumental for investors seeking to contextualise long‑term performance trends, as the Gujarat Themis Biosyn stock price movements illustrate how pharmaceutical industry fundamentals, regulatory cycles, and investor expectations converge in market pricing.
The Gujarat Themis Biosyn share price has shown distinct seasonal patterns over the past decade. The best performing periods have been those with successful product approvals and strong export demand. Historically, the stock has shown positive returns in most years of the past decade. In terms of annual performance, the Gujarat Themis Biosyn share price delivered its strongest returns in years when the company launched new products or expanded into new markets. The Gujarat Themis Biosyn share price has demonstrated that the stock tends to perform better in periods of strong export demand and supportive regulatory outcomes, while underperforming during phases of regulatory uncertainty and intense generic competition.
Gujarat Themis Biosyn Limited Investor Relevance and Role in Portfolio
Gujarat Themis Biosyn holds a position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on fermentation‑based API manufacturing. The company’s expertise in fermentation technology aligns it with investment strategies that value niche pharmaceutical manufacturing capabilities and export growth. The Gujarat Themis Biosyn share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector‑specific funds monitor regulatory approval indicators and product pipeline factors when evaluating allocation decisions.
Institutional stakeholders play a role in Gujarat Themis Biosyn’s ownership profile, with notable long‑term investment entities including quant Money Managers Ltd, ICICI Prudential Mutual Fund, and other institutional investors identified in shareholding data. Mutual fund holders of Gujarat Themis Biosyn encompass those that seek pharmaceutical exposure. Promoter holding remains unchanged at 70.86% in Mar 2026. FII/FPI have decreased holdings from 1.96% to 1.80% in Mar 2026, while Mutual Funds holding remains unchanged at 1.16% in Mar 2026, with 5 MF schemes. Domestic Institutional Investors (DII) hold 1.17%. These investors represent a blend of domestic and institutional perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.
Based on data, Gujarat Themis Biosyn exhibits varying levels of beta and volatility across different time horizons. Based on data, the long‑term beta of Gujarat Themis Biosyn stands at 1.97, indicating that the stock is generally more volatile than the broader market over an extended period. On a daily basis, the beta values are not consistently reported. Based on data, the weekly volatility has been moderate. Based on data, the mean values for long‑term range is not consistently reported. Standard deviations range from moderate to high across different periods. The Gujarat Themis Biosyn share price has shown periods of heightened responsiveness to sector‑specific news and quarterly earnings releases. The Gujarat Themis Biosyn stock price’s beta reflects that the company’s pharmaceutical manufacturing nature and niche API focus may provide some stability, though the pharma sector remains sensitive to regulatory changes and drug price fluctuations. The Gujarat Themis Biosyn share price has historically moved on regulatory approval news.
Gujarat Themis Biosyn Limited Sectoral Relevance and Peer Positioning
The sector relevance of Gujarat Themis Biosyn is anchored in its role within the broader Indian pharmaceutical industry, where it specialises in fermentation‑based APIs. As part of this industry, the company’s strategic positioning connects API production for regulated markets and formulation manufacturing for domestic use. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Ltd, Divi’s Laboratories Ltd, Torrent Pharmaceuticals Ltd, Aurobindo Pharma Ltd, Cipla Ltd, JB Chemicals & Pharmaceuticals Ltd, Cohance Lifesciences Ltd, Alivus Life Sciences Ltd, Themis Medicare Ltd, Kopran Ltd, and other API manufacturers. Firms with parallels in either API scale or specialty product focus are often referenced when evaluating relative performance and operational positioning within the sector.
In valuation terms, factors like the Gujarat Themis Biosyn P/E ratio have shown variations over different periods. The current P/E ratio stands at approximately 90.87, trading at a premium to the industry median of 40.40. The mean historical PE Ratio over the last ten years has fluctuated, reaching elevated levels during periods of strong earnings growth. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. The Gujarat Themis Biosyn P/E ratio decreased in some years when earnings grew and increased in others.
Similarly, the Gujarat Themis Biosyn EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. The current TTM EPS stands at approximately ₹4.39, with a book value per share of ₹22.79. Structural gains from API capacity expansion and new product filings supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from pricing pressure and raw material cost inflation have moderated EPS momentum. Gujarat Themis Biosyn earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. Gujarat Themis Biosyn market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market.
Over years, the Gujarat Themis Biosyn market cap has followed a pattern of strong growth followed by stability. From fiscal year 2016 onwards, the company’s market cap showed an increasing trend, reflecting strong investor confidence. The market cap increased from approximately ₹450 crore in 2018 to a peak of over ₹4,300 crore in 2025‑2026. This increase mirrors the rally in the Gujarat Themis Biosyn share price and the broader performance of the pharmaceutical sector during the COVID‑19 pandemic and post‑pandemic period.
The Gujarat Themis Biosyn earnings over the past ten years has been characterised by a period of strong growth. Net income showed a generally increasing trend, with reported net profit reaching ₹48.77 crore in FY 2025. The company’s revenue for FY 2025 was ₹150.8 crore, a decrease of 11% compared to the previous financial year, while profit after tax decreased by 18% compared to last year and stood at ₹48.8 crore. This recent earnings moderation reflects the impact of demand normalisation, increased competitive intensity, and regulatory changes on the company’s profitability.
The Gujarat Themis Biosyn P/E ratio has shown fluctuations over the ten‑year period. At the end of recent fiscal years, the P/E ratio varied, reaching 90.87 in 2026. The mean historical P/E ratio over the last ten years has been elevated due to low historical earnings. The current P/E ratio stands at a premium compared to the industry median, reflecting that investor expectations are pricing in future growth potential. The Gujarat Themis Biosyn share price has been influenced by these valuation metrics. The Gujarat Themis Biosyn stock price continues to be evaluated in the context of its earnings potential and market position.
Summary
Gujarat Themis Biosyn is a pharmaceutical company listed on both the NSE and BSE, where the Gujarat Themis Biosyn share price reflects regulatory policies, API demand cycles, and product pipeline progress within the pharma sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader pharmaceutical export themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s fermentation‑based API manufacturing market.
Gujarat Themis Shareholding Pattern
| Held By | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Promoter | 70.9 | 70.9 | 70.9 | 70.9 | 70.9 | 59.3 |
| FII | 2.5 | 3 | 2 | 1.8 | 1.8 | 3.8 |
| DII | 1.2 | 1.1 | 1.1 | 1.2 | 1.1 | 12.6 |
| Public | 25.4 | 25 | 26 | 26.2 | 26.2 | 24.2 |
Gujarat Themis Delivery And Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume Avg | Daily Avg Delivery Volume % |
|---|---|---|---|
| Day | 98.69 K | 2.06 L | 47.90% |
| Week | 97.39 K | 1.85 L | 52.72% |
| 1 Month | 1.17 L | 2.31 L | 50.55% |
| 6 Month | 1.61 L | 3.19 L | 50.60% |
Gujarat Themis SWOT Analysis
Benjamin Graham Value Screen
Expensive Performers (DVM)
PEG lower than Industry PEG
Companies with Zero Promoter Pledge
Companies with decreasing Promoter pledge
Volume Shockers
Gujarat Themis Corporate Action
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 23 Sep, 2026 | 0.67 | FINAL | 23 Sep, 2026 | Equity Share |
| 04 Sep, 2025 | 0.67 | FINAL | 05 Sep, 2025 | Equity Share |
| 15 Jul, 2024 | 0.25 | FINAL | Equity Share | |
| 22 Feb, 2024 | 0.75 | INTERIM | 22 Feb, 2024 | Equity Share |
| 01 Sep, 2023 | 1 | FINAL | Equity Share | |
| 01 Dec, 2022 | 4.4 | INTERIM | 02 Dec, 2022 | Equity Share |
| 29 Aug, 2022 | 4 | FINAL | Equity Share | |
| 24 Nov, 2021 | 2 | INTERIM | 25 Nov, 2021 | Equity Share |
| 24 Nov, 2021 | 5 | SPECIAL | 25 Nov, 2021 | Equity Share |
| 10 Sep, 2020 | 1.65 | FINAL | Equity Share |
Gujarat Themis Stock Comparison
Financials | ||||||
|---|---|---|---|---|---|---|
| Price (₹) | ₹191.75 | ₹499 | ₹5.20 | ₹236.31 | ₹25.55 | ₹514.40 |
| % Change | 1.70% | 0.49% | 0.97% | 0.77% | -0.04% | 1.20% |
| Revenue TTM (₹ Cr) | - | ₹667.67 | ₹69.99 | ₹303.42 | ₹279.64 | ₹528.95 |
| Net Profit TTM (₹ Cr) | - | ₹24.93 | ₹-176.47 | ₹18.33 | ₹35.68 | ₹57.29 |
| PE TTM | - | 88.00 | -0.20 | 49.70 | 3.80 | 25.70 |
| 1 Year Return | -71.65 | 26.67 | 415 | 91.84 | 70.29 | -28.62 |
| ROCE | - | 3.56 | -56.37 | - | 17.36 | 23.87 |
Similar Stocks
VALIANTLAB
Valiant Laboratories Ltd.
₹ 98.81
-1.99%
SUPRIYA
Supriya Lifescience Ltd.
₹ 614.45
-1.00%
SIGACHI
Sigachi Industries Ltd.
₹ 28.20
-1.43%
WINDLAS
Windlas Biotech Ltd.
₹ 993.00
-0.89%
VINEETLAB
Vineet Laboratories Ltd.
₹ 38.79
+4.70%
SOLARA
Solara Active Pharma Sciences Ltd.
₹ 650.00
-2.45%
ZIMLAB
Zim Laboratories Ltd.
₹ 134.89
-0.81%
MEDICO
Medico Remedies Ltd.
₹ 18.20
-1.99%
DCAL
Dishman Carbogen Amcis Ltd.
₹ 121.50
-6.78%
HALEOSLABS
Haleos Labs Ltd.
₹ 1615.60
-1.30%
ADVENZYMES
Advanced Enzyme Technologies Ltd.
₹ 280.95
-0.78%
BAJAJHCARE
Bajaj Healthcare Ltd.
₹ 321.95
+0.09%
ORTINGLOBE
Ortin Global Ltd.
₹ 13.00
-2.11%
BROOKS
Brooks Laboratories Ltd.
₹ 66.90
-1.33%
RPGLIFE
RPG Life Sciences Ltd.
₹ 2501.00
-1.85%
BAFNAPH
Bafna Pharmaceuticals Ltd.
₹ 470.40
-2.00%
ALPA
Alpa Laboratories Ltd.
₹ 51.60
-0.67%
SMSPHARMA
SMS Pharmaceuticals Ltd.
₹ 475.25
-2.46%
NECLIFE
Nectar Lifesciences Ltd.
₹ 9.97
-2.64%
MANGALAM
Mangalam Drugs and Organics Ltd.
₹ 28.36
-2.17%
INDOCO
Indoco Remedies Ltd.
₹ 239.40
+6.41%
INDSWFTLAB
Ind-Swift Laboratories Ltd.
₹ 336.00
+1.24%
LINCOLN
Lincoln Pharmaceuticals Ltd.
₹ 512.85
-1.47%
PANACEABIO
Panacea Biotec Ltd.
₹ 352.25
-0.13%
FAQ's on GUJTHEM
What is the current share price of Gujarat Themis Biosyn Ltd.?
What is the Market Capitalization of Gujarat Themis Biosyn Ltd.?
What are the PE and PB ratios for Gujarat Themis Biosyn Ltd.?
What is the 52-Week High and Low for Gujarat Themis Biosyn Ltd.?
What is the current dividend yield for Gujarat Themis Biosyn Ltd.?
Who are the major shareholders of Gujarat Themis Biosyn Ltd.?
Who are the peers of Gujarat Themis Biosyn Ltd. in the Pharmaceuticals & Biotechnology sector?
What is the latest dividend information for Gujarat Themis Biosyn Ltd.?
What is the shareholding pattern for Gujarat Themis Biosyn Ltd.?
By signing up I certify terms, conditions & privacy policy

